Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
1.
Am J Transplant ; 17(8): 2078-2091, 2017 Aug.
Article in English | MEDLINE | ID: mdl-28422412

ABSTRACT

Long-term clinicopathological studies of BK-associated nephropathy (PyVAN) are not available. We studied 206 biopsies (71 patients), followed 3.09 ± 1.46 years after immunosuppression reduction. The biopsy features (% immunostain for PyV large T ag + staining and inflammation ± acute rejection) were correlated with viral load dynamics and serum creatinine to define the clinicopathological status (PyVCPS). Incidence of acute rejection was 28% in the second biopsy and 50% subsequently (25% mixed T cell-mediated allograft rejection (TCMR) + antibody-mediated allograft rejection (AMR); rejection overall affected 38% of patients (>50% AMR). Graft loss was 15.4% (0.8-5.3 years after PyVAN); 76% had complete viral clearance (mean 28 weeks). The only predictors of graft loss were acute rejection (TCMR p = 0.008, any type p = 0.07), and increased "t" and "ci" in the second biopsy (p = 0.006 and 0.048). Higher peak viremia correlated with poorer viral clearance (p = 0.002). Presumptive and proven PyVAN had similar presentation, evolution, and outcome. Late PyVAN (>2 years, 9.8%) justifies BK viremia evaluation at any point with graft dysfunction and/or biopsy evaluation. This study describes the histological evolution of PyVAN and corresponding clinicopathological correlations. Although the pathological features overall reflect the viral and immunological interactions, the PyVAN course remains difficult to predict based on any single feature. Appropriate clinical management requires repeat biopsies and determination of the PyVCPS at relevant time points, for corresponding personalized immunosuppression adjustment.


Subject(s)
Graft Rejection/pathology , Kidney Diseases/pathology , Kidney Transplantation/adverse effects , Polyomavirus Infections/pathology , Postoperative Complications , Tumor Virus Infections/pathology , Viremia/pathology , Adult , Aged , Aged, 80 and over , BK Virus/isolation & purification , BK Virus/pathogenicity , Cohort Studies , Female , Follow-Up Studies , Glomerular Filtration Rate , Graft Rejection/etiology , Graft Survival , Humans , Kidney Diseases/etiology , Kidney Function Tests , Male , Middle Aged , Polyomavirus Infections/etiology , Prognosis , Risk Factors , Transplantation, Homologous , Tumor Virus Infections/etiology , Viral Load , Viremia/etiology
2.
Am J Transplant ; 17(2): 551-556, 2017 Feb.
Article in English | MEDLINE | ID: mdl-27458893

ABSTRACT

Renal transplant has become an important option for human immunodeficiency virus (HIV)-infected patients with end-stage renal disease; however, these patients experience a high rate of acute cellular rejection (ACR). Guidelines do not currently exist for the optimal duration of viral suppression prior to transplantation. In a retrospective cohort analysis of 47 HIV-infected renal transplant recipients, we compared the rate of ACR between patients based on the length of time of viral suppression prior to transplantation. Of the patients who achieved viral suppression for >6 months but less than 2 years prior to transplantation (n = 15), 60% experienced ACR compared to 41% of patients suppressed at least 2 years or more (n = 32) prior to transplant (p = 0.21). Patients suppressed <2 years experienced ACR at 2.48 times the rate of those suppressed 2 years or longer. Induction immunosuppression, HLA mismatch and panel-reactive antibodies (PRAs) did not significantly differ between the two groups.


Subject(s)
Anti-HIV Agents/therapeutic use , Graft Rejection/etiology , HIV Infections/complications , HIV-1/pathogenicity , Kidney Failure, Chronic/surgery , Kidney Transplantation/adverse effects , Adult , Aged , Female , Follow-Up Studies , Graft Rejection/diagnosis , Graft Survival , HIV Infections/drug therapy , HIV Infections/virology , Humans , Kidney Failure, Chronic/epidemiology , Male , Middle Aged , Postoperative Complications , Prognosis , Retrospective Studies , Risk Factors
3.
Transpl Infect Dis ; 18(2): 247-50, 2016 Apr.
Article in English | MEDLINE | ID: mdl-26782090

ABSTRACT

A 58-year-old renal transplant recipient underwent biopsy 11 weeks post transplantation for increasing creatinine. The biopsy showed cytomegalovirus (CMV) glomerulitis together with BK polyomavirus (BKPyV)-associated nephropathy (PVAN). Treatment with intravenous ganciclovir and overall reduction in maintenance immunosuppression resulted in prompt resolution of the CMV glomerulitis, but with persistence of PVAN in a follow-up biopsy 4 weeks later. Stable creatinine and BKPyV viral clearance were observed at the last clinical visit 15 months post transplantation. This case exemplifies infectious glomerulitis, which requires differentiation from the more common glomerulitis caused by antibody-mediated allograft rejection. The morphological similarities and differences between BKPyV and CMV infections are discussed.


Subject(s)
BK Virus/isolation & purification , Cytomegalovirus Infections/diagnosis , Kidney Glomerulus/virology , Kidney Transplantation/adverse effects , Polyomavirus Infections/virology , Tumor Virus Infections/virology , Cytomegalovirus/isolation & purification , Cytomegalovirus Infections/pathology , Cytomegalovirus Infections/virology , Graft Rejection , Humans , Immunocompromised Host , Kidney/pathology , Kidney/virology , Kidney Glomerulus/pathology , Male , Middle Aged , Polyomavirus Infections/pathology , Postoperative Complications , Tissue Donors , Tumor Virus Infections/pathology
4.
Transplant Proc ; 45(4): 1469-71, 2013 May.
Article in English | MEDLINE | ID: mdl-23726599

ABSTRACT

Although mast cells (MC) play an ambiguous role in acute rejection, they have been implicated in chronic fibrotic processes overall and also in the kidney. Their morphological assessment in the context of comprehensive renal allograft pathology has not been sufficiently addressed, however. Using the CD117 immunostain in 461 consecutive kidney allograft biopsy specimens we counted the number of MC in the most inflamed biopsy area. The number of MC was correlated with the presence of the Banff defined features of T-cell-mediated and antibody-mediated rejection. No correlation was found between the number of MC and the presence or degree of T-cell-mediated rejection or with most parameters defining acute or chronic antibody-mediated rejection. Significant correlation was found, however, with the degree of interstitial fibrosis (IF; P = .000), and time post- transplantation (P = .000). Peritubular C4d staining correlated negatively with the number of MC (P = .000). Correlation of MC infiltration and peritubular capillary multilamellation (P = .000) indicated an association between general interstitial and microvascular chronic pathology. We conclude that MC represent a somewhat unique cellular component that correlates poorly with parameters of active T-cell or antibody-mediated allograft rejection. In contrast, because MC correlate strongly with IF and time post-transplantation, they could potentially be valuable as a surrogate marker for the cumulative burden of tissue injury.


Subject(s)
Kidney Transplantation , Mast Cells/cytology , Biopsy , Graft Rejection , Humans
5.
Am J Transplant ; 11(9): 1943-50, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21812917

ABSTRACT

The association of serum uric acid (UA) with kidney transplant outcomes is uncertain. We examined the predictive value of UA during the first year posttransplant as a time-varying factor for graft survival after adjustment for time-dependent and independent confounding factors. Four hundred and eighty-eight renal allograft recipients transplanted from January 2004 to June 2006 and followed for 41.1 ± 17.7 months were included. Data on UA, estimated glomerular filtration rate (eGFR), tacrolimus level, mycophenolate mofetil (MMF) and prednisone doses, use of allopurinol, angiotensin-converting enzyme-inhibitor/angiotensin-receptor-blocker (ACEi/ARB) and diuretics at 1, 3, 6, 9 and 12 months were collected. Primary endpoint of the study was graft loss, defined as graft failure and death. Cox proportional hazard models and generalized estimating equations were used for analysis. UA level was associated with eGFR, gender, retransplantation, decease-donor organ, delayed graft function, diuretics, ACEi/ARB and MMF dose. After adjustment for these confounders, UA was independently associated with increased risk of graft loss (HR: 1.15, p = 0.003; 95% CI: 1.05-1.27). Interestingly, UA interacted with eGFR (HR: 0.996, p < 0.05; 95% CI: 0.993-0.999 for interaction term). Here, we report a significant association between serum UA during first year posttransplant and graft loss, after adjustment for corresponding values of time-varying variables including eGFR, immunosuppressive drug regimen and other confounding factors. Its negative impact seems to be worse with lower eGFR.


Subject(s)
Graft Survival , Kidney Transplantation , Uric Acid/blood , Adult , Aged , Glomerular Filtration Rate , Humans , Male , Middle Aged , Proportional Hazards Models
6.
Am J Transplant ; 11(9): 1792-802, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21812920

ABSTRACT

The first Banff proposal for the diagnosis of pancreas rejection (Am J Transplant 2008; 8: 237) dealt primarily with the diagnosis of acute T-cell-mediated rejection (ACMR), while only tentatively addressing issues pertaining to antibody-mediated rejection (AMR). This document presents comprehensive guidelines for the diagnosis of AMR, first proposed at the 10th Banff Conference on Allograft Pathology and refined by a broad-based multidisciplinary panel. Pancreatic AMR is best identified by a combination of serological and immunohistopathological findings consisting of (i) identification of circulating donor-specific antibodies, and histopathological data including (ii) morphological evidence of microvascular tissue injury and (iii) C4d staining in interacinar capillaries. Acute AMR is diagnosed conclusively if these three elements are present, whereas a diagnosis of suspicious for AMR is rendered if only two elements are identified. The identification of only one diagnostic element is not sufficient for the diagnosis of AMR but should prompt heightened clinical vigilance. AMR and ACMR may coexist, and should be recognized and graded independently. This proposal is based on our current knowledge of the pathogenesis of pancreas rejection and currently available tools for diagnosis. A systematized clinicopathological approach to AMR is essential for the development and assessment of much needed therapeutic interventions.


Subject(s)
Autoantibodies/immunology , Graft Rejection/diagnosis , Pancreas Transplantation/immunology , Practice Guidelines as Topic , Graft Rejection/immunology , Humans
8.
Histol Histopathol ; 25(2): 189-96, 2010 02.
Article in English | MEDLINE | ID: mdl-20017105

ABSTRACT

Sirolimus is associated with prolonged delayed graft function (DGF) following renal transplantation and exacerbation of proteinuria. We assessed renal allograft biopsies from DGF patients treated with de novo sirolimus (n = 10) for renal tubular cell and podocyte apoptosis and expression of activated caspase-3, Bcl-2, and mTOR and compared them to biopsies from DGF patients not receiving sirolimus (n = 15). Both groups received mycophenolate mofetil, prednisone and antibody induction. Apoptosis was assessed using terminal deoxynucleodidyl transferase mediated dUTP nick end labeling (TUNEL) staining. Caspase-3, Bcl-2, and mTOR expression were assessed by immunohistochemistry. Sirolimus treated patients had 334+/-69 TUNEL positive cells per 5 high power fields compared to 5.5+/-2.9 TUNEL positive cells in control patients (p<0.001). The number of TUNEL positive cells correlated with tubular architectural disruption. Expression of activated caspase-3, Bcl-2, or activated mTOR did not differ between groups. 60% of biopsies from sirolimus treated patients compared to 7% of biopsies from controls showed diffuse podocyte apoptosis (p = 0.007). There was no podocyte expression of activated mTOR, activated caspase-3, or Bcl-2 in either group. These data suggest that DGF patients treated with sirolimus have increased renal tubular cell apoptosis and podocyte apoptosis.


Subject(s)
Apoptosis/drug effects , Delayed Graft Function/chemically induced , Epithelial Cells/drug effects , Immunosuppressive Agents/adverse effects , Kidney Transplantation/adverse effects , Kidney Tubules/drug effects , Podocytes/drug effects , Sirolimus/adverse effects , Adult , Biopsy , Caspase 3/analysis , Delayed Graft Function/metabolism , Delayed Graft Function/pathology , Drug Therapy, Combination , Epithelial Cells/chemistry , Epithelial Cells/pathology , Female , Humans , Immunohistochemistry , In Situ Nick-End Labeling , Intracellular Signaling Peptides and Proteins/analysis , Kidney Tubules/chemistry , Kidney Tubules/pathology , Male , Middle Aged , Mycophenolic Acid/analogs & derivatives , Mycophenolic Acid/therapeutic use , Podocytes/chemistry , Podocytes/pathology , Prednisone/therapeutic use , Protein Serine-Threonine Kinases/analysis , Proto-Oncogene Proteins c-bcl-2/analysis , Retrospective Studies , TOR Serine-Threonine Kinases , Transplantation, Homologous , Treatment Outcome
9.
Am J Transplant ; 9(12): 2758-67, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19845596

ABSTRACT

We examined the pattern of PTC C4d by immunohistochemistry and DSA in 297 kidney recipients with indication biopsies, and evaluated their predictive value for graft survival. Median biopsy time was 5.1 months posttransplant. Patients were followed for 17.9 +/- 9.4 months postbiopsy. An 18.5% had focal and 15.2% had diffuse C4d, with comparable graft survival (adjusted graft failure HR: 2.3, p = 0.001; HR:1.9, p < 0.02, respectively). 31.3% were DSA+, 19.5% class I and 22.9% class II DSA. Only those with class II DSA had worse outcome (adjusted HR:2.5, p = 0.001 for class II only; HR:2.7, p < 0.001 for class I/II DSA). Among patients with <10%C4d, 23.9% had DSA, compared to 68.9% with diffuse staining. For patients biopsied in first-year posttransplant presence of DSA, regardless of C4d positivity in biopsy, was a poor prognostic factor (adjusted graft failure HR: 4.2, p < 0.02 for C4d-/DSA+; HR:4.9, p = 0.001 for C4d+/DSA+), unlike those biopsied later. We have shown that focal C4d had similar impact on graft survival as diffuse pattern. During the first-year posttransplant either class I or II DSA, and afterward only class II DSA were associated with worse graft survival. DSA was predictive of worse outcome regardless of C4d for patients biopsied in first year and only with C4d positivity afterward, supporting the importance of assessment of both DSA and C4d pattern in biopsy.


Subject(s)
Antibodies/physiology , Biopsy , Complement C4b/immunology , Graft Survival/immunology , Kidney Transplantation/immunology , Kidney Transplantation/pathology , Peptide Fragments/immunology , Tissue Donors , Adult , Aged , Cohort Studies , Female , Graft Rejection/immunology , Humans , Immunohistochemistry , Kidney/pathology , Male , Middle Aged , Retrospective Studies
10.
Am J Transplant ; 9(3): 536-42, 2009 Mar.
Article in English | MEDLINE | ID: mdl-19191764

ABSTRACT

The long-term graft outcomes after positive cross-match (PXM) living donor kidney transplantation (LDKT) are unknown and the descriptive published data present short-medium term results. We conducted a retrospective cohort study of LDKT with PXM by flow cytometry performed at our center during February 1999 to October 2006, compared to a control group, matched 1:1 for age, sex, race, retransplantation and transplant year. The PXM group was treated with a course of plasmapheresis/low-dose intravenous immunoglobulin (IVIg) preoperatively, and OKT3 or thymoglobulin induction. Both groups (n = 41 each) were comparable except for duration of end-stage renal disease (ESRD), induction, HLA mismatch and panel-reactive antibody (PRA). During the period of up to 9 years, 14 PXM and 7 controls lost their grafts (p < 0.04). Graft survival rates at 1 and 5 years were 89.9% and 69.4% for PXM group and 97.6% and 80.6% for the controls, respectively. PXM was associated with higher risk of graft loss (HR 2.6, p = 0.04; 95%CI 1.03-6.4) (t(1/2)= 6.8 years), but not with patient survival (HR 1.96, p = 0.29; 95%CI 0.6-7.0) or 1-year serum creatinine (beta= 0.06, p = 0.59 for ln (SCr); 95% CI -0.16 to 0.28). These results suggest that despite the favorable short-term results of PXM LDKT after PP/IVIg conditioning, medium-long-term outcomes are notably worse than expected, perhaps comparable to non-ECD deceased donor kidney transplantation (KT).


Subject(s)
Histocompatibility Antigens/immunology , Kidney Transplantation/immunology , Kidney Transplantation/statistics & numerical data , Living Donors/statistics & numerical data , Adult , Creatine/blood , Female , Graft Survival/immunology , Humans , Male , Time Factors , Treatment Outcome
11.
Am J Transplant ; 9(2): 337-47, 2009 Feb.
Article in English | MEDLINE | ID: mdl-19067659

ABSTRACT

We undertook this study to assess the rate of poor early graft function (EGF) after laparoscopic live donor nephrectomy (lapNx) and to determine whether poor EGF is associated with diminished long-term graft survival. The study population consisted of 946 consecutive lapNx donors/recipient pairs at our center. Poor EGF was defined as receiving hemodialysis on postoperative day (POD) 1 through POD 7 (delayed graft function [DGF]) or serum creatinine >/= 3.0 mg/dL at POD 5 without need for hemodialysis (slow graft function [SGF]). The incidence of poor EGF was 16.3% (DGF 5.8%, SGF 10.5%), and it was stable in chronologic tertiles. Poor EGF was independently associated with worse death-censored graft survival (adjusted hazard ratio (HR) 2.15, 95% confidence interval (CI) 1.34-3.47, p = 0.001), worse overall graft survival (HR 1.62, 95% CI 1.10-2.37, p = 0.014), worse acute rejection-free survival (HR 2.75, 95% CI 1.92-3.94, p < 0.001) and worse 1-year renal function (p = 0.002). Even SGF independently predicted worse renal allograft survival (HR 2.54, 95% CI 1.44-4.44, p = 0.001). Risk factors for poor DGF included advanced donor age, high recipient BMI, sirolimus use and prolonged warm ischemia time. In conclusion, poor EGF following lapNx has a deleterious effect on long-term graft function and survival.


Subject(s)
Delayed Graft Function/physiopathology , Graft Rejection/epidemiology , Graft Survival/physiology , Kidney Transplantation/physiology , Kidney/physiopathology , Living Donors , Nephrectomy , Adult , Body Mass Index , Cohort Studies , Creatinine/blood , Female , Graft Rejection/diagnosis , Humans , Incidence , Laparoscopy , Male , Middle Aged , Postoperative Complications , Renal Dialysis , Risk Factors , Tissue and Organ Harvesting , Transplantation, Homologous , Treatment Outcome , Warm Ischemia
12.
Am J Transplant ; 8(11): 2316-24, 2008 Nov.
Article in English | MEDLINE | ID: mdl-18801024

ABSTRACT

Despite the common use of diagnostic pretransplant deceased donor kidney biopsy, there is no consensus on the prognostic significance of the pathologic findings. In order to assist clinicians with interpretation we analyzed 371 pretransplant biopsies and correlated the findings with graft failure. Glomerular pathology was assessed with percent glomerulosclerosis (GS), glomerular size and periglomerular fibrosis (PGF); vascular pathology with arterial wall-to-lumen ratio (WLR) and arteriolar hyalinosis and interstitial pathology with measurement of cumulative fibrosis and presence of scar. Using two-thirds of the study population as a model-development cohort, we found that biopsy features independently associated with an increased risk of graft failure were GS > or =15%, interlobular arterial WLR > or =0.5 and the presence of PGF, arteriolar hyalinosis or scar. The Maryland Aggregate Pathology Index (MAPI), was developed from these parameters and validated on the remaining one-third of the population. Five-year actuarial graft survival was 90% for kidneys with MAPI scores between 0 and 7, 63% for scores from 8 to 11 and 53% for scores from 12 to 15 (p < 0.001). We conclude MAPI may help transplant physicians estimate graft survival from the preimplantation biopsy findings, in clinical situations similar to this study population (cold ischemia over 24 h, GS < 25%).


Subject(s)
Biopsy/methods , Kidney Transplantation/mortality , Kidney Transplantation/methods , Adolescent , Adult , Aged , Child , Child, Preschool , Cohort Studies , Female , Graft Survival , Humans , Kidney/pathology , Kidney Diseases/diagnosis , Kidney Diseases/pathology , Kidney Transplantation/statistics & numerical data , Male , Maryland , Middle Aged , Treatment Outcome
13.
Am J Transplant ; 6(10): 2396-402, 2006 Oct.
Article in English | MEDLINE | ID: mdl-16869806

ABSTRACT

There are limited data on the results of early steroid withdrawal (ESW) in African-American (AA) renal allograft recipients. We examined short-term transplant outcomes in a retrospective, non-concurrent cohort study of 40 AAs who did not (ESW group), and 33 who did [steroid maintenance (SM) group] receive maintenance steroids after day 4 post-transplant. Patients received thymoglobulin (ATG) induction, mycophenolate mofetil, and tacrolimus or sirolimus. Data were analyzed using survival analysis methods and regression models. Patients in the ESW group were older, had lower current panel reactive antibody and fewer re-transplants, and received fewer doses of ATG. One-year graft survival and acute rejection (AR) rates were 100% and 13% in the ESW group and 97% and 15% in the SM group. After controlling for confounders, at 1 year, ESW was not associated with higher risk of graft loss, AR, or worse graft function, but was associated with less weight gain. The SM group had higher cholesterol levels at 3 months and higher risk of post-transplant diabetes mellitus. We did not observe any cases of subclinical rejection. This study suggests that ESW under modern immunosuppression is safe over the short term in at least a subset of AA recipients with risk profiles similar to those studied herein, and could be associated with improved outcomes.


Subject(s)
Black or African American , Diabetes Mellitus/ethnology , Diabetes Mellitus/etiology , Glucocorticoids/therapeutic use , Graft Rejection/drug therapy , Kidney Transplantation , Adult , Biopsy , Female , Follow-Up Studies , Graft Rejection/pathology , Humans , Male , Middle Aged , Retrospective Studies , Risk Factors , Time Factors , Treatment Outcome , Weight Gain
14.
SELECTION OF CITATIONS
SEARCH DETAIL
...